Scinai Immunotherapeutics (SCNI) Competitors

$0.56 +0.02 (+4.44%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.00 (+0.18%)

As of 07:28 AM Eastern

SCNI vs. PCSA, BMRA, RNAZ, MTVA, and TCRT

Should you buy Scinai Immunotherapeutics stock or one of its competitors? MarketBeat compares Scinai Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scinai Immunotherapeutics include Heatwurx (PCSA), Biomerica (BMRA), TransCode Therapeutics (RNAZ), MetaVia (MTVA), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry.

How does Scinai Immunotherapeutics compare to Heatwurx?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Heatwurx. MarketBeat recorded 1 mentions for Scinai Immunotherapeutics and 0 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.89 beat Scinai Immunotherapeutics' score of 0.41 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Heatwurx	Very Positive

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Scinai Immunotherapeutics' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Heatwurx	N/A	-281.31%	-200.80%

Scinai Immunotherapeutics has higher revenue and earnings than Heatwurx. Heatwurx is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.51	-$8.31M	-$9.57	N/A
Heatwurx	N/A	N/A	-$13.56M	-$8.00	N/A

Heatwurx has a consensus price target of $25.00, suggesting a potential upside of 809.09%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts plainly believe Heatwurx is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scinai Immunotherapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Heatwurx on 8 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Biomerica?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Scinai Immunotherapeutics and 0 mentions for Biomerica. Scinai Immunotherapeutics' average media sentiment score of 0.41 beat Biomerica's score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Biomerica	Neutral

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scinai Immunotherapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Scinai Immunotherapeutics' return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Biomerica	-96.49%	-98.14%	-70.42%

Biomerica has higher revenue and earnings than Scinai Immunotherapeutics. Biomerica is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.51	-$8.31M	-$9.57	N/A
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A

Biomerica has a consensus price target of $9.00, indicating a potential upside of 300.00%. Given Biomerica's higher probable upside, analysts clearly believe Biomerica is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Biomerica has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Biomerica on 9 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Scinai Immunotherapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-702.37%	-71.51%
Scinai Immunotherapeutics	N/A	N/A	N/A

TransCode Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Scinai Immunotherapeutics has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Scinai Immunotherapeutics	$1.31M	1.51	-$8.31M	-$9.57	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 1.47 beat Scinai Immunotherapeutics' score of 0.41 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TransCode Therapeutics	Positive
Scinai Immunotherapeutics	Neutral

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats TransCode Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to MetaVia?

Scinai Immunotherapeutics (NASDAQ:SCNI) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Scinai Immunotherapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
MetaVia	N/A	-172.92%	-89.39%

MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,701.80%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scinai Immunotherapeutics has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.51	-$8.31M	-$9.57	N/A
MetaVia	N/A	N/A	-$12.97M	-$8.36	N/A

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 0.8% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MetaVia had 6 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 7 mentions for MetaVia and 1 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 0.41 beat MetaVia's score of 0.04 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scinai Immunotherapeutics beats MetaVia on 9 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Alaunos Therapeutics has a beta of -1.13, meaning that its stock price is 213% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Alaunos Therapeutics has higher earnings, but lower revenue than Scinai Immunotherapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$5K	1,220.22	-$4.18M	-$2.13	N/A
Scinai Immunotherapeutics	$1.31M	1.51	-$8.31M	-$9.57	N/A

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 1 mentions for Scinai Immunotherapeutics. Alaunos Therapeutics' average media sentiment score of 0.98 beat Scinai Immunotherapeutics' score of 0.41 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scinai Immunotherapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-143.05%	-107.89%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

Alaunos Therapeutics and Scinai Immunotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.90M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-0.06	18.13	20.64	25.23
Price / Sales	1.51	289.87	554.85	79.36
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.72	6.57	9.66	6.63
Net Income	-$8.31M	$24.35M	$3.56B	$335.59M
7 Day Performance	5.07%	-2.53%	-1.65%	-1.20%
1 Month Performance	0.90%	-3.55%	-2.60%	-1.16%
1 Year Performance	-80.14%	53.51%	30.07%	28.10%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	0.4156 of 5 stars	$0.56 +4.4%	N/A	-80.6%	$1.90M	$1.31M	N/A	20	Gap Up
PCSA Heatwurx	3.2532 of 5 stars	$3.07 +20.4%	$25.00 +714.3%	-53.1%	$7.01M	N/A	N/A	20	Gap Up High Trading Volume
BMRA Biomerica	1.2576 of 5 stars	$2.41 +7.1%	$9.00 +273.4%	-38.2%	$6.95M	$5.31M	N/A	60	Positive News High Trading Volume
RNAZ TransCode Therapeutics	0.765 of 5 stars	$6.94 -0.5%	N/A	-24.4%	$6.39M	N/A	N/A	9	Positive News Earnings Report
MTVA MetaVia	2.2721 of 5 stars	$1.19 -0.8%	$26.50 +2,126.9%	-85.3%	$6.20M	N/A	N/A	8	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. PCSA, BMRA, RNAZ, MTVA, and TCRT

How does Scinai Immunotherapeutics compare to Heatwurx?

Summary

How does Scinai Immunotherapeutics compare to Biomerica?

Summary

How does Scinai Immunotherapeutics compare to TransCode Therapeutics?

Summary

How does Scinai Immunotherapeutics compare to MetaVia?

Summary

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. PCSA, BMRA, RNAZ, MTVA, and TCRT

How does Scinai Immunotherapeutics compare to Heatwurx?

Does the media refer more to SCNI or PCSA?

Do institutionals and insiders hold more shares of SCNI or PCSA?

Is SCNI or PCSA more profitable?

Which has stronger valuation and earnings, SCNI or PCSA?

Do analysts recommend SCNI or PCSA?

Which has more volatility and risk, SCNI or PCSA?

Summary

How does Scinai Immunotherapeutics compare to Biomerica?

Does the media refer more to SCNI or BMRA?

Do institutionals and insiders have more ownership in SCNI or BMRA?

Is SCNI or BMRA more profitable?

Which has better valuation and earnings, SCNI or BMRA?

Do analysts rate SCNI or BMRA?

Which has more risk & volatility, SCNI or BMRA?

Summary

How does Scinai Immunotherapeutics compare to TransCode Therapeutics?

Is RNAZ or SCNI more profitable?

Which has more volatility and risk, RNAZ or SCNI?

Which has preferable earnings and valuation, RNAZ or SCNI?

Do analysts prefer RNAZ or SCNI?

Does the media prefer RNAZ or SCNI?

Do insiders and institutionals hold more shares of RNAZ or SCNI?

Summary

How does Scinai Immunotherapeutics compare to MetaVia?

Which has more volatility & risk, SCNI or MTVA?

Is SCNI or MTVA more profitable?

Do analysts rate SCNI or MTVA?

Which has higher earnings & valuation, SCNI or MTVA?

Do insiders and institutionals have more ownership in SCNI or MTVA?

Does the media refer more to SCNI or MTVA?

Summary

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Which has more volatility and risk, TCRT or SCNI?

Which has higher earnings & valuation, TCRT or SCNI?

Does the media favor TCRT or SCNI?

Do analysts recommend TCRT or SCNI?

Do insiders & institutionals have more ownership in TCRT or SCNI?

Is TCRT or SCNI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools